Genmab A/S (NASDAQ:GMAB) Upgraded at Wall Street Zen

Key Points

• Genmab A/S has been upgraded from a "hold" rating to a "buy" rating by Wall Street Zen, indicating increased investor confidence in the company's stock.
• HC Wainwright and Truist Financial have also issued "buy" ratings with adjusted price targets of $37.00 and $46.00 respectively, showcasing varying outlooks among analysts.
• The company's recent quarterly earnings report revealed earnings per share of $0.31, exceeding analyst expectations, but the revenue of $715 million fell short of the $5.17 billion forecast.

Genmab A/S (NASDAQ:GMAB - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued to investors on Monday.

Several other research firms have also recently commented on GMAB. HC Wainwright restated a "buy" rating and set a $37.00 price target (down previously from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th. Truist Financial boosted their price target on shares of Genmab A/S from $45.00 to $46.00 and gave the stock a "buy" rating in a research note on Tuesday, July 8th. Finally, Sanford C. Bernstein cut shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a report on Tuesday, April 1st. One research analyst has rated the stock with a sell rating, three have given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Genmab A/S has an average rating of "Moderate Buy" and an average price target of $37.80.

Genmab A/S Stock Performance

NASDAQ GMAB opened at $23.40 on Monday. The firm's fifty day moving average is $21.49 and its two-hundred day moving average is $20.80. Genmab A/S has a one year low of $17.24 and a one year high of $28.56. The firm has a market cap of $15.01 billion, a PE ratio of 13.30, a P/E/G ratio of 7.11 and a beta of 0.94.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.08. Genmab A/S had a return on equity of 18.08% and a net margin of 35.11%. The firm had revenue of $715.00 million for the quarter, compared to analysts' expectations of $5.17 billion. Research analysts predict that Genmab A/S will post 1.45 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Yousif Capital Management LLC lifted its holdings in shares of Genmab A/S by 7.8% in the second quarter. Yousif Capital Management LLC now owns 10,943 shares of the company's stock valued at $226,000 after purchasing an additional 790 shares in the last quarter. CWM LLC increased its position in Genmab A/S by 50.5% during the second quarter. CWM LLC now owns 1,797 shares of the company's stock worth $37,000 after buying an additional 603 shares in the last quarter. Vanguard Personalized Indexing Management LLC raised its holdings in shares of Genmab A/S by 24.7% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 52,684 shares of the company's stock worth $1,088,000 after acquiring an additional 10,426 shares during the last quarter. Blue Trust Inc. lifted its position in shares of Genmab A/S by 33.2% in the second quarter. Blue Trust Inc. now owns 9,871 shares of the company's stock valued at $204,000 after acquiring an additional 2,458 shares in the last quarter. Finally, Callan Family Office LLC acquired a new stake in shares of Genmab A/S during the second quarter valued at $655,000. Hedge funds and other institutional investors own 7.07% of the company's stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.